Literature DB >> 18667492

Effector CD4+ T-cell involvement in clearance of infectious herpes simplex virus type 1 from sensory ganglia and spinal cords.

Alison J Johnson1, Chin-Fun Chu, Gregg N Milligan.   

Abstract

In primary infection, CD8(+) T cells are important for clearance of infectious herpes simplex virus (HSV) from sensory ganglia. In this study, evidence of CD4(+) T-cell-mediated clearance of infectious HSV type 1 (HSV-1) from neural tissues was also detected. In immunocompetent mice, HSV-specific CD4(+) T cells were present in sensory ganglia and spinal cords coincident with HSV-1 clearance from these sites and remained detectable at least 8 months postinfection. Neural CD4(+) T cells isolated at the peak of neural infection secreted gamma interferon, tumor necrosis factor alpha, interleukin-2 (IL-2), or IL-4 after stimulation with HSV antigen. HSV-1 titers in neural tissues were greatly reduced over time in CD8(+) T-cell-deficient and CD8(+) T-cell-depleted mice, suggesting that CD4(+) T cells could mediate clearance of HSV-1 from neural tissue. To examine possible mechanisms by which CD4(+) T cells resolved neural infection, CD8(+) T cells were depleted from perforin-deficient or FasL-defective mice. Clearance of infectious virus from neural tissues was not significantly different in perforin-deficient or FasL-defective mice compared to wild-type mice. Further, in spinal cords and brains after vaginal HSV-1 challenge of chimeric mice expressing both perforin and Fas or neither perforin nor Fas, virus titers were significantly lower than in control mice. Thus, perforin and Fas were not required for clearance of infectious virus from neural tissues. These results suggest that HSV-specific CD4(+) T cells are one component of a long-term immune cell presence in neural tissues following genital HSV-1 infection and play a role in clearance of infectious HSV-1 at neural sites, possibly via a nonlytic mechanism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18667492      PMCID: PMC2546982          DOI: 10.1128/JVI.01159-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  67 in total

1.  Dendritic cell-induced memory T cell activation in nonlymphoid tissues.

Authors:  Linda M Wakim; Jason Waithman; Nico van Rooijen; William R Heath; Francis R Carbone
Journal:  Science       Date:  2008-01-11       Impact factor: 47.728

2.  Perforin-dependent neurologic injury in a viral model of multiple sclerosis.

Authors:  P D Murray; D B McGavern; X Lin; M K Njenga; J Leibowitz; L R Pease; M Rodriguez
Journal:  J Neurosci       Date:  1998-09-15       Impact factor: 6.167

3.  Synergistic roles of antibody and interferon in noncytolytic clearance of Sindbis virus from different regions of the central nervous system.

Authors:  Rebeca Burdeinick-Kerr; Jennifer Wind; Diane E Griffin
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103

4.  CD4+ T-cell responses are required for clearance of West Nile virus from the central nervous system.

Authors:  Elizabeth M Sitati; Michael S Diamond
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

5.  Neutrophils aid in protection of the vaginal mucosae of immune mice against challenge with herpes simplex virus type 2.

Authors:  G N Milligan
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

6.  Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine.

Authors:  David I Bernstein; Fred Y Aoki; Stephen K Tyring; Lawrence R Stanberry; Claude St-Pierre; Stephen D Shafran; Geert Leroux-Roels; Koen Van Herck; Anne Bollaerts; Gary Dubin
Journal:  Clin Infect Dis       Date:  2005-03-24       Impact factor: 9.079

7.  Tumor necrosis factor (TNF) protects resistant C57BL/6 mice against herpes simplex virus-induced encephalitis independently of signaling via TNF receptor 1 or 2.

Authors:  Patric Lundberg; Paula V Welander; Carl K Edwards; Nico van Rooijen; Edouard Cantin
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

8.  Long-term presence of virus-specific plasma cells in sensory ganglia and spinal cord following intravaginal inoculation of herpes simplex virus type 2.

Authors:  Gregg N Milligan; Michael G Meador; Chin-Fun Chu; Christal G Young; Talitha L Martin; Nigel Bourne
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

9.  Fas ligand interactions contribute to CD8+ T-cell-mediated control of West Nile virus infection in the central nervous system.

Authors:  Bimmi Shrestha; Michael S Diamond
Journal:  J Virol       Date:  2007-09-05       Impact factor: 5.103

10.  Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia.

Authors:  Georges M G M Verjans; Rogier Q Hintzen; Jessica M van Dun; Angelique Poot; Johannes C Milikan; Jon D Laman; Anton W Langerak; Paul R Kinchington; Albert D M E Osterhaus
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-20       Impact factor: 11.205

View more
  39 in total

1.  Inflammation in neuroviral diseases.

Authors:  Pascale Giraudon; Arlette Bernard
Journal:  J Neural Transm (Vienna)       Date:  2010-08       Impact factor: 3.575

2.  Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone.

Authors:  Sita Awasthi; John M Lubinski; Carolyn E Shaw; Shana M Barrett; Michael Cai; Fushan Wang; Michael Betts; Susan Kingsley; Daniel J Distefano; John W Balliet; Jessica A Flynn; Danilo R Casimiro; Janine T Bryan; Harvey M Friedman
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

3.  Increased protection from vaccinia virus infection in mice genetically prone to lymphoproliferative disorders.

Authors:  Mina O Seedhom; Keisha S Mathurin; Sung-Kwon Kim; Raymond M Welsh
Journal:  J Virol       Date:  2012-03-21       Impact factor: 5.103

4.  The expression of IL-2 and IL-4 in CD4(+) T cells from mouse lymph nodes and spleen during HSV-1-induced facial palsy.

Authors:  Lintao Gu; Yuechen Han; Wenwen Liu; Yanyan Mao; Jianfeng Li; Haibo Wang
Journal:  Inflamm Res       Date:  2013-11-27       Impact factor: 4.575

5.  Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs.

Authors:  Richard Brans; Feng Yao
Journal:  BMC Microbiol       Date:  2010-06-03       Impact factor: 3.605

6.  Herpes simplex virus (HSV)-specific T cells activated in the absence of IFN-gamma express alternative effector functions but are not protective against genital HSV-2 infection.

Authors:  Alison J Johnson; Michelle H Nelson; Melanie D Bird; Chin-Fun Chu; Gregg N Milligan
Journal:  J Reprod Immunol       Date:  2009-11-25       Impact factor: 4.054

Review 7.  New concepts in herpes simplex virus vaccine development: notes from the battlefield.

Authors:  Gargi Dasgupta; Aziz A Chentoufi; Anthony B Nesburn; Steven L Wechsler; Lbachir BenMohamed
Journal:  Expert Rev Vaccines       Date:  2009-08       Impact factor: 5.217

8.  Potent adjuvant activity of cationic liposome-DNA complexes for genital herpes vaccines.

Authors:  David I Bernstein; Rhonda D Cardin; Fernando J Bravo; Jane E Strasser; Nicholas Farley; Claudia Chalk; Marla Lay; Jeff Fairman
Journal:  Clin Vaccine Immunol       Date:  2009-03-11

9.  Race between retroviral spread and CD4+ T-cell response determines the outcome of acute Friend virus infection.

Authors:  Rebecca Pike; Andrew Filby; Mickaël J-Y Ploquin; Urszula Eksmond; Rute Marques; Inês Antunes; Kim Hasenkrug; George Kassiotis
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

10.  Dendritic cells and B cells maximize mucosal Th1 memory response to herpes simplex virus.

Authors:  Norifumi Iijima; Melissa M Linehan; Melodie Zamora; Debbie Butkus; Robert Dunn; Marilyn R Kehry; Terri M Laufer; Akiko Iwasaki
Journal:  J Exp Med       Date:  2008-12-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.